Waters Corporation
General ticker "WAT" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $20.7B (TTM average)
Waters Corporation follows the US Stock Market performance with the rate: 14.7%.
Estimated limits based on current volatility of 1.5%: low 393.66$, high 405.25$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 8200 (+3.8%) as of 2024
- China accounted for 13.5% of revenue in the fiscal year ended 2024-12-31
- US accounted for 31.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Currency fluctuations, Geopolitical risks, Public health crises, Supply chain disruptions, Economic downturns and volatility
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [336.94$, 451.70$]
- 2025-12-31 to 2026-12-31 estimated range: [355.13$, 478.27$]
Financial Metrics affecting the WAT estimates:
- Negative: with PPE of 31.1 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 28.04 > 18.64
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 40.15 <= 41.86
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.29 > 6.04
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -4.48 < Investing cash flow per share per price, % of -0.66
- Positive: Industry inventory ratio change (median), % of -0.79 <= -0.15
Short-term WAT quotes
Long-term WAT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,971.96MM | $2,956.42MM | $2,946.82MM |
| Operating Expenses | $2,098.56MM | $2,138.74MM | $2,120.47MM |
| Operating Income | $873.39MM | $817.68MM | $826.35MM |
| Non-Operating Income | $-35.55MM | $-81.43MM | $-71.48MM |
| Interest Expense | $48.80MM | $98.86MM | $89.68MM |
| R&D Expense | $185.99MM | $174.94MM | $183.03MM |
| Income(Loss) | $837.85MM | $736.24MM | $754.87MM |
| Taxes | $130.09MM | $94.01MM | $117.03MM |
| Profit(Loss)* | $707.75MM | $642.23MM | $637.83MM |
| Stockholders Equity | $504.49MM | $1,150.34MM | $1,828.51MM |
| Inventory | $455.71MM | $516.24MM | $477.26MM |
| Assets | $3,281.45MM | $4,626.85MM | $4,553.80MM |
| Operating Cash Flow | $611.66MM | $602.81MM | $762.12MM |
| Capital expenditure | $183.46MM | $160.63MM | $142.48MM |
| Investing Cash Flow | $-107.97MM | $-1,442.27MM | $-144.02MM |
| Financing Cash Flow | $-509.63MM | $754.95MM | $-696.67MM |
| Earnings Per Share** | $11.80 | $10.87 | $10.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.